Welcome to our dedicated page for Gt Biopharma news (Ticker: GTBP), a resource for investors and traders seeking the latest updates and insights on Gt Biopharma stock.
GT Biopharma develops clinical-stage immuno-oncology therapeutics based on its proprietary TriKE® natural killer cell engager platform. News around GTBP focuses on candidate-specific development updates for GTB-3650, a TriKE® program for relapsed or refractory CD33-expressing hematologic malignancies, and GTB-5550, a B7-H3-targeted TriKE® program for solid tumors known to express B7-H3.
Company updates also cover FDA investigational new drug activity, Phase 1 trial enrollment and safety-review disclosures, R&D spending, liquidity commentary and periodic financial results. GT Biopharma also issues investor-conference announcements as it presents its NK cell engager strategy and clinical pipeline to the capital markets.
GT Biopharma, Inc. (NASDAQ: GTBP) has adjourned its 2022 Special Shareholders Meeting to October 10, 2022, at 11 a.m. PST due to a lack of quorum. The meeting aims to ratify the inclusion of discretionary votes by brokers for a proposal to reduce the company’s authorized shares of common stock from 750 million to 250 million. Shareholders on record as of August 8, 2022, are encouraged to vote by 11:59 p.m. PST on October 9, 2022. Those who have already voted do not need to recast their votes unless wishing to change them.
GT Biopharma (NASDAQ: GTBP) announced key findings from its accepted abstract at the ESMO Congress 2022, highlighting the efficacy of its product candidate GTB-5550. This compound specifically targets B7-H3+ solid tumors, generating a strong NK cell proliferation signal surpassing that of IL-15 alone. GTB-5550 has shown promising results in inducing NK cell degranulation and interferon gamma production against various malignancies. Ongoing in vivo activity in human tumor xenogeneic models further supports these findings. The company anticipates submitting an IND application in 2023.
GT Biopharma, Inc. (NASDAQ: GTBP) will present at H.C. Wainwright’s 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, at the Lotte New York Palace. The presentation is set for September 13, from 10:30 to 11:00 am EDT. This clinical-stage immuno-oncology company focuses on innovative therapeutics utilizing its proprietary NK cell engager, TriKE®. Management will also engage in 1x1 meetings with attendees. A webcast of the presentation will be available for replay for 90 days following the event.
GT Biopharma, Inc. (NASDAQ: GTBP) announced a Settlement and Investment Agreement with Cytovance Biologics for the registration of its investigational new drug GTB-3650. The IND application with the FDA is expected by March 31, 2023. GTB-3650 aims to treat relapsed/refractory acute myelogenous leukemia and high-risk myelodysplastic syndrome, and offers several advantages over its predecessor, GTB-3550, including improved potency and a fully owned proprietary molecule. Payments to Cytovance will be limited to 4.9% of total shares outstanding.
GT Biopharma reported its Q2 fiscal 2022 results, revealing a net loss of $3.0 million, down from $8.4 million in Q2 2021. Total cash as of June 30, 2022, stands at $23.7 million, providing a runway into 2023. R&D expenses increased to $1.1 million for Q2, while S,G&A expenses decreased to $1.9 million from $3.7 million year-over-year. The company showcased promising preclinical data at EHA 2022 and has plans for IND applications for GTB-3650 and GTB-5550 in 2023, focusing on advancing their TriKE® platform.
GT Biopharma announced its preclinical findings on GTB-7550, a CD19-targeted tri-specific killer engager, at the EHA 2022 Congress. The research indicates that GTB-7550 enhances NK cell function against B-cell malignancies, particularly chronic lymphocytic leukemia (CLL). CLL, which accounts for a significant portion of leukemia cases, currently has limited effective treatment options. The results suggest GTB-7550 could address these shortcomings in CLL therapy. Future studies will assess GTB-7550's efficacy against other hematologic cancers.
GT Biopharma reported significant progress in its TriKE® platform at the AACR 2022, showcasing preclinical data for GTB-5550, which activates NK cells against head and neck squamous cell carcinomas. The company has $26.7 million in cash as of March 31, 2022, ensuring funding into 2023. R&D expenses rose to $2.1 million due to expanded staffing and product development. General and Administrative expenses fell to $3.4 million, reflecting reduced stock-based compensation. The net loss narrowed to $5.4 million, or $0.17 per share, compared to a loss of $29.7 million a year prior.
GT Biopharma, Inc. (NASDAQ: GTBP) will present at H.C. Wainwright’s Hybrid Global Investment Conference from May 23-26, 2022, at Fontainebleau, Miami Beach. The presentation is scheduled for May 24, 2022, from 2:00 to 2:30 PM EDT. GT Biopharma focuses on developing immuno-oncology therapeutics leveraging its proprietary TriKE® NK cell engager platform, which enhances the immune system's ability to combat cancer. A replay of the presentation will be available for 90 days. For more details, visit GT Biopharma's corporate website.
GT Biopharma presented pre-clinical data on GTB-5550 at the AACR Annual Meeting 2022. This novel B7H3-targeted tri-specific killer engager (TriKE) activates natural killer (NK) cells to target head and neck squamous cell carcinomas (HNSCC). The study demonstrated that GTB-5550 significantly enhances NK cell degranulation and target cell killing compared to IL-15 or B7H3 alone. The findings suggest GTB-5550's potential for targeting HNSCC, particularly in patients who are intolerant to traditional therapies.
GT Biopharma reported its financial results for Q4 and the full year of 2021, highlighting a cash position of $32.0 million as of December 31, 2021, which provides funding into 2023 for clinical development of its lead products GTB-3650 and GTB-5550. The company presented novel TriKE® data at recent medical conferences, showing promising activation of NK cells against tumors. However, GT Biopharma reported a net loss of $18.0 million in Q4 and $58.0 million for the full year, significantly higher than the previous year's losses, raising concerns for investors.